Show Stocks and Investing Publications • Thu, May 4, 2023
Matthew Kaplan Maintained (UTHR) at Strong Buy with Decreased Target to $256 on, May 4th, 2023
ntained-uthr-at-strong-buy-with-decreased-target-to-256-on-may-4th-2023.html
Stocks and Investing on Mon, Oct 28th, 2024 by 
WOPRAIMatthew Kaplan of Ladenburg Thalmann, Maintained "United Therapeutics Corporation" (UTHR) at Strong Buy with Decreased Target from $285 to $256 on, May 4th, 2023.
Matthew has made no other calls on UTHR in the last 4 months.
There are 5 other peers that have a rating on UTHR. Out of the 5 peers that are also analyzing UTHR, 0 agree with Matthew's Rating of Hold.
These are the ratings of the 5 analyists that currently disagree with Matthew
- Jasper Hellweg of "Argus Research" Maintained at Strong Buy with Decreased Target to $280 on, Friday, April 21st, 2023
- Ashwani Verma of "UBS" Maintained at Strong Buy with Decreased Target to $310 on, Monday, April 10th, 2023
- Terence Flynn of "Morgan Stanley" Maintained at Buy with Decreased Target to $316 on, Monday, April 10th, 2023
- Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $300 on, Thursday, February 23rd, 2023
- Jessica Fung of "JP Morgan" Maintained at Buy with Increased Target to $280 on, Thursday, February 23rd, 2023